BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

427 related articles for article (PubMed ID: 25583566)

  • 1. EGFR tyrosine kinase inhibitors versus cranial radiation therapy for EGFR mutant non-small cell lung cancer with brain metastases: a systematic review and meta-analysis.
    Soon YY; Leong CN; Koh WY; Tham IW
    Radiother Oncol; 2015 Feb; 114(2):167-72. PubMed ID: 25583566
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of the benefit of sequential cranial radiotherapy in patients with EGFR mutant non-small cell lung cancer and brain metastasis.
    Byeon S; Ham JS; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
    Med Oncol; 2016 Aug; 33(8):97. PubMed ID: 27447711
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Deferring Radiation Therapy in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Who Develop Brain Metastases.
    Magnuson WJ; Yeung JT; Guillod PD; Gettinger SN; Yu JB; Chiang VL
    Int J Radiat Oncol Biol Phys; 2016 Jun; 95(2):673-9. PubMed ID: 27034176
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of Brain Metastases in Tyrosine Kinase Inhibitor-Naïve Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer: A Retrospective Multi-Institutional Analysis.
    Magnuson WJ; Lester-Coll NH; Wu AJ; Yang TJ; Lockney NA; Gerber NK; Beal K; Amini A; Patil T; Kavanagh BD; Camidge DR; Braunstein SE; Boreta LC; Balasubramanian SK; Ahluwalia MS; Rana NG; Attia A; Gettinger SN; Contessa JN; Yu JB; Chiang VL
    J Clin Oncol; 2017 Apr; 35(10):1070-1077. PubMed ID: 28113019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Icotinib versus whole-brain irradiation in patients with EGFR-mutant non-small-cell lung cancer and multiple brain metastases (BRAIN): a multicentre, phase 3, open-label, parallel, randomised controlled trial.
    Yang JJ; Zhou C; Huang Y; Feng J; Lu S; Song Y; Huang C; Wu G; Zhang L; Cheng Y; Hu C; Chen G; Zhang L; Liu X; Yan HH; Tan FL; Zhong W; Wu YL
    Lancet Respir Med; 2017 Sep; 5(9):707-716. PubMed ID: 28734822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Timing of Whole Brain Radiotherapy on Survival of Patients with EGFR-mutated 
Non-small Cell Lung Cancer and Brain Metastases].
    Liu G; Zhang X; Tian C; Xia G; Liu P; Zhang Q; Li X; Zhang H; Qin N; Wang J; Zhang S
    Zhongguo Fei Ai Za Zhi; 2016 Aug; 19(8):501-7. PubMed ID: 27561798
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment options for patients with brain metastases from EGFR/ALK-driven lung cancer.
    Doherty MK; Korpanty GJ; Tomasini P; Alizadeh M; Jao K; Labbé C; Mascaux CM; Martin P; Kamel-Reid S; Tsao MS; Pintilie M; Liu G; Bradbury PA; Feld R; Leighl NB; Chung C; Shepherd FA
    Radiother Oncol; 2017 May; 123(2):195-202. PubMed ID: 28363487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical outcome of tyrosine kinase inhibitors alone or combined with radiotherapy for brain metastases from epidermal growth factor receptor (EGFR) mutant non small cell lung cancer (NSCLC).
    Zhu Q; Sun Y; Cui Y; Ye K; Yang C; Yang D; Ma J; Liu X; Yu J; Ge H
    Oncotarget; 2017 Feb; 8(8):13304-13311. PubMed ID: 28076323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prolonged survival of patients with EGFR-mutated non-small cell lung cancer with solitary brain metastases treated with surgical resection of brain and lung lesions followed by EGFR TKIs.
    Gui Q; Liu J; Li D; Xu C
    World J Surg Oncol; 2017 Oct; 15(1):184. PubMed ID: 29037198
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of EGFR-TKIs with or without upfront brain radiotherapy for EGFR-mutant NSCLC patients with central nervous system metastases.
    Saida Y; Watanabe S; Abe T; Shoji S; Nozaki K; Ichikawa K; Kondo R; Koyama K; Miura S; Tanaka H; Okajima M; Terada M; Ishida T; Tsukada H; Makino M; Iwashima A; Sato K; Matsumoto N; Yoshizawa H; Kikuchi T
    Thorac Cancer; 2019 Nov; 10(11):2106-2116. PubMed ID: 31507098
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radiotherapy for asymptomatic brain metastasis in epidermal growth factor receptor mutant non-small cell lung cancer without prior tyrosine kinase inhibitors treatment: a retrospective clinical study.
    Liu S; Qiu B; Chen L; Wang F; Liang Y; Cai P; Zhang L; Chen Z; Liu S; Liu M; Liu H
    Radiat Oncol; 2015 May; 10():118. PubMed ID: 26014133
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimal Sequence of Local and EGFR-TKI Therapy for EGFR-Mutant Non-Small Cell Lung Cancer With Brain Metastases Stratified by Number of Brain Metastases.
    Miyawaki E; Kenmotsu H; Mori K; Harada H; Mitsuya K; Mamesaya N; Kawamura T; Kobayashi H; Nakashima K; Omori S; Wakuda K; Ono A; Naito T; Murakami H; Endo M; Nakasu Y; Gon Y; Takahashi T
    Int J Radiat Oncol Biol Phys; 2019 Jul; 104(3):604-613. PubMed ID: 30851347
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intracranial disease control for EGFR-mutant and ALK-rearranged lung cancer with large volume or symptomatic brain metastases.
    Dutta SW; Mack ML; Aliotta E; Ward KA; Muller DA; Larner JM; Fadul CE; Hall RD; Gentzler RD; Sheehan JP
    J Neurooncol; 2020 Sep; 149(2):357-366. PubMed ID: 32902767
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EGFR TKIs plus WBRT Demonstrated No Survival Benefit Other Than That of TKIs Alone in Patients with NSCLC and EGFR Mutation and Brain Metastases.
    Jiang T; Su C; Li X; Zhao C; Zhou F; Ren S; Zhou C; Zhang J
    J Thorac Oncol; 2016 Oct; 11(10):1718-28. PubMed ID: 27237825
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of epidermal growth factor receptor-tyrosine kinase inhibitors alone on EGFR-mutant non-small cell lung cancer with brain metastasis.
    Zhang Q; Zhang X; Yan H; Jiang B; Xu C; Yang J; Chen Z; Su J; Wu YL; Zhou Q
    Thorac Cancer; 2016 Nov; 7(6):648-654. PubMed ID: 27755835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Upfront Cranial Radiotherapy vs. EGFR Tyrosine Kinase Inhibitors Alone for the Treatment of Brain Metastases From Non-small-cell Lung Cancer: A Meta-Analysis of 1465 Patients.
    Du XJ; Pan SM; Lai SZ; Xu XN; Deng ML; Wang XH; Yao DC; Wu SX
    Front Oncol; 2018; 8():603. PubMed ID: 30619745
    [No Abstract]   [Full Text] [Related]  

  • 17. Intracranial control and survival outcome of tyrosine kinase inhibitor (TKI) alone versus TKI plus radiotherapy for brain metastasis of epidermal growth factor receptor-mutant non-small cell lung cancer.
    Sung S; Lee SW; Kwak YK; Kang JH; Hong SH; Kim YS
    J Neurooncol; 2018 Aug; 139(1):205-213. PubMed ID: 29644484
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Upfront Cranial Radiotherapy Followed by Erlotinib Positively Affects Clinical Outcomes of Epidermal Growth Factor Receptor-mutant Non-small Cell Lung Cancer With Brain Metastases.
    Saruwatari K; Ikeda T; Saeki S; Shingu N; Imamura K; Komatu T; Ushijima S; Maruyama H; Kashiwabara K; Tomita Y; Ichiyasu H; Fujii K; Sakagami T
    Anticancer Res; 2019 Feb; 39(2):923-931. PubMed ID: 30711977
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of up-front radiotherapy and TKI with TKI alone for NSCLC with brain metastases and EGFR mutation: A meta-analysis.
    Wang C; Lu X; Lyu Z; Bi N; Wang L
    Lung Cancer; 2018 Aug; 122():94-99. PubMed ID: 30032853
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radiotherapy plus EGFR TKIs in non-small cell lung cancer patients with brain metastases: an update meta-analysis.
    Jiang T; Min W; Li Y; Yue Z; Wu C; Zhou C
    Cancer Med; 2016 Jun; 5(6):1055-65. PubMed ID: 26990668
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.